Tenofovir disoproxil fumarate (Viread)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: HIV, Chronic Hepatitis B

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (2)
EU
  • Viread: treatment of chronic hepatitis B in adults (European Commission extension of indication, April 2008)gilead.com
  • HIV 1 infection Viread 123 mg film coated tablets are indicated in combination with other antiretroviral medicinal products for the treatment of HIV 1 infected paediatric patients, with NRTI resistance or toxicities precluding the use of first line agents, aged 6 to < 12 years who weigh from 17 kg to less than 22 kg. The choice of Viread to treat antiretroviral experienced patients with HIV 1 infection should be based on individual viral resistance testing and/or treatment history of patients. Hepatitis B infection Viread 123 mg film coated tablets are indicated for the treatment of...
    EMA
Product first approved 2002

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (65)
Chronic Hepatitis B
NCT04704024 · University of Alabama at Birmingham
2021-09-03 – 2026-12-31 · Hepatitis B Infection
What this study did
NCT03343431 · Institut de Recherche pour le Developpement
2018-08-02 – 2025-06-30 · Hepatitis B, Pregnancy
What this study did
NCT04392700 · Sun Yat-sen University
2019-07-25 – 2024-07-25 · Hepatocellular Carcinoma Recurrent
What this study did
NCT03903796 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
2018-08-16 – 2024-06-07 · Chronic HBV Infection
What this study did
NCT02600117 · University Health Network, Toronto
2016-01-26 – 2023-02-28 · Hepatitis B, Chronic
What this study did
NCT03887702 · SWOG Cancer Research Network
2020-01-17 – 2022-12-20 · Hepatitis B Infection, Malignant Solid Neoplasm
What this study did
NCT01369212 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2012-11 – 2021-03-08 · Hepatitis B
What this study did
NCT02186574 · University Health Network, Toronto
2015-05 – 2021-02 · Hepatitis B, Lymphoma, Non-Hodgkin
What this study did
NCT03236584 · Uijeongbu St. Mary Hospital
2015-09-01 – 2019-03-30 · Proportion of Patients With a Sustained Virological Response (Serum HBV DNA <20 IU/mL) at Week 48
What this study did
NCT01745822 · Institut de Recherche pour le Developpement
2013-01 – 2018-10 · Hepatitis B Chronic Infection, Pregnancy
What this study did
NCT01872988 · Taichung Veterans General Hospital
2012-09 – 2018-02 · Chronic Hepatitis B, Hepatocellular Carcinoma
What this study did
NCT01300234 · GlaxoSmithKline
2011-03-30 – 2016-12-06 · Hepatitis B
What this study did
NCT01848743 · Kaohsiung Veterans General Hospital.
2013-04 – 2016-10 · Chronic HBV With Severe Exacerbation
What this study did
NCT01480284 · GlaxoSmithKline
2011-11 – 2014-11 · Hepatitis B, Chronic
What this study did
NCT01475851 · GlaxoSmithKline
2011-12 – 2014-10 · Hepatitis B, Chronic
What this study did
NCT01063036 · Bristol-Myers Squibb
2010-05 – 2014-02 · Chronic Hepatitis B
What this study did
NCT00221286 · University Hospital, Bonn
2004-09 – 2007-01 · Chronic Hepatitis B, HIV Infections
What this study did
HIV
NCT06203132 · ANRS, Emerging Infectious Diseases
2025-01-27 – 2029-01 · HIV-1-infection
What this study did
NCT07075146 · José Antonio Mata Marín
2025-05-05 – 2028-08-01 · HIV - Human Immunodeficiency Virus, Obesity, Overweight and/or Obesity
What this study did
NCT04925752 · Gilead Sciences
2021-06-28 – 2028-08 · Pre-Exposure Prophylaxis of HIV Infection
What this study did
NCT04994509 · Gilead Sciences
2021-08-30 – 2028-01 · Pre-Exposure Prophylaxis of HIV Infection
What this study did
NCT06133686 · MRC/UVRI and LSHTM Uganda Research Unit
2024-04-01 – 2027-04-01 · HIV
What this study did
NCT05457530 · Prism Health North Texas
2022-08-01 – 2023-05-03 · Body Weight Changes, Human Immunodeficiency Virus, ART, Obesity, Minority Health, BMD, Metabolic Syndrome, Fasting
What this study did
NCT04433780 · Professor Francois Venter
2021-01-04 – 2023-03-31 · HIV-1-infection
What this study did
NCT04303598 · Henan Genuine Biotech Co., Ltd.
2020-04-01 – 2022-08-01 · HIV-infection/Aids
What this study did
NCT03122262 · Professor Francois Venter
2017-01-16 – 2022-07-29 · HIV-1 Infection
What this study did
NCT02777229 · ANRS, Emerging Infectious Diseases
2016-07 – 2021-07 · HIV-1 Infection
What this study did
NCT03563742 · Janssen Research & Development, LLC
2018-09-24 – 2021-06-28 · Human Immunodeficiency Virus Infections
What this study did
NCT02870790 · Kirby Institute
2016-03 – 2020-10 · HIV, STI
What this study did
NCT03327155 · Kirby Institute
2017-11-16 – 2020-07-20 · HIV Prevention
What this study did
NCT02231281 · Yongtao Sun, MD, PhD
2014-08 – 2018-12 · Acute HIV Infection
What this study did
NCT01352117 · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
2011-11-18 – 2018-11-29 · HIV-1 Infection, Kaposi's Sarcoma
What this study did
NCT01705574 · Gilead Sciences
2012-10-24 – 2018-09-06 · Acquired Immunodeficiency Syndrome, HIV Infections
What this study did
NCT01694420 · Duke University
2012-09 – 2017-02 · HIV
What this study did
NCT02670772 · Willem Daniel Francois Venter
2012-07 – 2015-12 · Acquired Immune Deficiency Syndrome, Human Immunodeficiency Virus
What this study did
NCT00074581 · National Institute of Allergy and Infectious Diseases (NIAID)
2005-02 – 2015-05 · HIV Infections
What this study did
NCT01363011 · Gilead Sciences
2011-05 – 2015-02 · Acquired Immunodeficiency Syndrome, HIV Infections
What this study did
Phase 2/3 (8)
Chronic Hepatitis B
NCT02555943 · Humanity and Health Research Centre
2015-02 – 2021-08 · Chronic Hepatitis C Infection, HBV Coinfection, Hepatitis B Reactivation
What this study did
HIV
NCT02720094 · National Institute of Allergy and Infectious Diseases (NIAID)
2016-12-19 – 2025-03-31 · HIV Infections
What this study did
NCT02150993 · ANRS, Emerging Infectious Diseases
2016-01-26 – 2019-05-15 · HIV-2 Infection
What this study did
NCT01721109 · Gilead Sciences
2012-12-06 – 2018-01-29 · Acquired Immunodeficiency Syndrome, HIV Infections
What this study did
NCT00078182 · National Institute of Allergy and Infectious Diseases (NIAID)
— · HIV Infections, HIV Seronegativity
What this study did
NCT02776748 · University of Washington
2015-01 – 2015-12 · HIV Pre-exposure Prophylaxis During Breastfeeding
What this study did
NCT00039741 · National Institute of Allergy and Infectious Diseases (NIAID)
2002-08 – 2010-03 · HIV Infections
What this study did
NCT00111150 · Centers for Disease Control and Prevention
2005-09 – 2007-03 · HIV Infection
What this study did
Phase 2 (56)
Chronic Hepatitis B
NCT04114890 · University of Oxford
2021-01-08 – 2023-09-29 · Hepatitis B, Tenofovir, Pregnancy
What this study did
NCT04189276 · Tasly Tianjin Biopharmaceutical Co., Ltd.
2019-12-10 – 2021-12 · Hepatitis B Virus (HBV)
What this study did
NCT02888106 · Hepatera Ltd.
2016-04 – 2020-10-30 · Chronic Viral Hepatitis B With Delta-agent
What this study did
NCT02565719 · Replicor Inc.
2016-03 – 2019-05 · Chronic Hepatitis B
What this study did
NCT02577029 · Arrowhead Pharmaceuticals
2015-12 – 2016-12 · Hepatitis B, Hepatitis D
What this study did
NCT00936715 · Gilead Sciences
2009-08 – 2015-11 · Chronic Hepatitis B
What this study did
NCT01334567 · Gilead Sciences
2010-08 – 2013-12 · Hepatitis B
What this study did
NCT00507689 · Gilead Sciences
2007-09 – 2011-05 · Chronic Hepatitis B
What this study did
NCT00307489 · Gilead Sciences
2006-03 – 2010-10 · Chronic Hepatitis B
What this study did
NCT00033163 · National Institute of Allergy and Infectious Diseases (NIAID)
est. completion 2005-05 · HIV Infections, Hepatitis B
What this study did
HIV
NCT04375800 · Merck Sharp & Dohme LLC
2021-02-03 – 2034-04-11 · Human Immunodeficiency Virus (HIV) Infection
What this study did
NCT06034938 · University Hospital, Caen
2024-02-08 – 2026-05-01 · Hiv
What this study did
NCT06435026 · University of North Carolina, Chapel Hill
2024-06-18 – 2026-02-11 · HIV, Prevention, Pregnancy
What this study did
NCT05630872 · National Institute of Allergy and Infectious Diseases (NIAID)
2024-02-13 – 2025-11-12 · HIV-associated Tuberculosis
What this study did
NCT04692077 · National Institute of Allergy and Infectious Diseases (NIAID)
2020-02-19 – 2023-07-07 · HIV Infections
What this study did
NCT04824131 · National Institute of Allergy and Infectious Diseases (NIAID)
2020-11-04 – 2023-01-10 · HIV Infections
What this study did
NCT03593655 · National Institute of Allergy and Infectious Diseases (NIAID)
2019-01-14 – 2021-09-09 · HIV Infections
What this study did
NCT02386098 · ViiV Healthcare
2015-07-08 – 2017-06-07 · HIV Infections
What this study did
NCT01903031 · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
2014-12-30 – 2016-10-10 · HIV-1 Infection
What this study did
NCT01505114 · National Institute of Allergy and Infectious Diseases (NIAID)
2012-06 – 2015-11 · HIV Infection
What this study did
NCT01160120 · The HIV Netherlands Australia Thailand Research Collaboration
2010-06 – 2015-06 · HIV
What this study did
NCT01515813 · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
2011-11 – 2014-12 · HIV-1 Infection
What this study did
NCT01327651 · HIV Prevention Trials Network
2011-08 – 2014-12 · HIV Infections
What this study did
NCT01400412 · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
2012-01-17 – 2014-06-30 · HIV-1 Infection
What this study did
NCT01403051 · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
2011-09 – 2013-02 · HIV-1 Infection
What this study did
NCT00705679 · National Institute of Allergy and Infectious Diseases (NIAID)
2009-08 – 2012-08 · HIV Infections
What this study did
NCT01033942 · University of North Carolina, Chapel Hill
2009-08 – 2011-09 · HIV
What this study did
NCT00592124 · National Institute of Allergy and Infectious Diseases (NIAID)
2008-06 – 2010-07 · HIV Infections
What this study did
NCT00214890 · University of California, San Diego
2004-12-07 – 2010-04-27 · HIV Infections
What this study did
NCT00441298 · Centre for the AIDS Programme of Research in South Africa
2007-05 – 2010-03 · HIV Infections
What this study did
NCT00334256 · French National Agency for Research on AIDS and Viral Hepatitis
2006-10 – 2009-12 · HIV Infection, Pregnancy
What this study did
NCT00131677 · Centers for Disease Control and Prevention
2005-02 – 2009-08 · HIV Infection
What this study did
NCT00350272 · Alexion Pharmaceuticals, Inc.
2006-05 – 2009-04 · HIV Infections
What this study did
NCT00102206 · National Institute of Allergy and Infectious Diseases (NIAID)
est. completion 2007-05 · HIV Infections
What this study did
NCT00038220 · Abbott
started 2000-07 · HIV Infections
What this study did
NCT00088309 · National Cancer Institute (NCI)
2004-06 – 2006-05 · HIV Infections
What this study did
NCT00122486 · FHI 360
2004-07 – 2006-03 · HIV Infections
What this study did
NCT00122512 · FHI 360
— · HIV Infections
What this study did
NCT00036452 · National Institute of Allergy and Infectious Diseases (NIAID)
est. completion 2006-01 · HIV Infections
What this study did
NCT00002415 · Gilead Sciences
— · HIV Infections
What this study did
NCT00027339 · National Institute of Allergy and Infectious Diseases (NIAID)
est. completion 2005-06 · HIV Infections
What this study did
NCT00270556 · Gilead Sciences
2003-01 – 2004-10 · HIV
What this study did
NCT00046033 · National Institute of Allergy and Infectious Diseases (NIAID)
est. completion 2003-03 · HIV Infections
What this study did
Phase 1/2 (13)
Chronic Hepatitis B
NCT06150014 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2023-12-07 – 2026-09 · Chronic Hepatitis b
What this study did
NCT05612581 · Vir Biotechnology, Inc.
2023-05-10 – 2025-08-19 · Hepatitis B, Chronic
What this study did
NCT02995005 · Johns Hopkins Bloomberg School of Public Health
2018-05-24 – 2023-01-31 · Hepatitis B
What this study did
NCT03109730 · Assembly Biosciences
2017-06-15 – 2018-06-12 · Chronic Hepatitis B
What this study did
HIV
NCT03332095 · National Institute of Allergy and Infectious Diseases (NIAID)
2018-07-02 – 2022-05-25 · HIV Infections
What this study did
NCT03251144 · University of California, Los Angeles
2019-04-01 – 2021-07-01 · HIV/AIDS, Antiviral Toxicity, Antiviral Drug Adverse Reaction, Mitochondrial Alteration
What this study did
NCT02475915 · SEARCH Research Foundation
2015-01 – 2016-03 · Acute HIV Infection
What this study did
NCT00931346 · International AIDS Vaccine Initiative
2009-10 – 2010-10 · HIV Infection
What this study did
NCT00971230 · International AIDS Vaccine Initiative
2009-10 – 2010-07 · HIV Infections
What this study did
NCT00260078 · National Institute of Allergy and Infectious Diseases (NIAID)
2006-02 – 2009-04 · HIV Infections
What this study did
Other / comorbidity
NCT03304717 · Children's Hospital of Philadelphia
2025-12 – 2029-12 · Aicardi Goutières Syndrome
What this study did
NCT01528865 · University of Michigan Rogel Cancer Center
2015-12 – 2017-08 · Lymphoma
What this study did
Phase 1 (42)
Chronic Hepatitis B
NCT07553767 · Ningbo No.2 Hospital
2026-03-31 – 2035-12-31 · Hepatocellular Carcinoma, HEPATITIS B CHRONIC, Hepatitis B Chronic Infection
What this study did
NCT07295873 · Beijing Continent Pharmaceutical Co, Ltd.
2026-03-15 – 2026-05-29 · Chronic Hepatitis B Liver Fibrosis, DDI (Drug-Drug Interaction)
What this study did
NCT05550519 · Janssen Pharmaceutica N.V., Belgium
2022-10-31 – 2025-08-28 · Hepatitis B, Chronic
What this study did
NCT05423106 · Janssen Research & Development, LLC
2022-07-04 – 2023-03-20 · Healthy, Hepatitis B, Chronic
What this study did
NCT03596697 · Hepion Pharmaceuticals, Inc.
2019-07-09 – 2021-06-04 · Hepatitis B, Infectious Disease, Liver Diseases
What this study did
NCT03662568 · Sunshine Lake Pharma Co., Ltd.
2018-06-26 – 2019-06-10 · Chronic Hepatitis B
What this study did
NCT02908191 · Assembly Biosciences
2016-11 – 2018-06-12 · Chronic Hepatitis B
What this study did
NCT03032536 · Alios Biopharma Inc.
2017-01-31 – 2017-06-28 · Hepatitis B, Chronic Hepatitis B, Viral Hepatitis B
What this study did
NCT01671787 · Gilead Sciences
2012-03 – 2013-04 · Chronic Hepatitis B
What this study did
NCT01480622 · GlaxoSmithKline
2011-12-05 – 2011-12-30 · Hepatitis B, Chronic
What this study did
HIV
NCT03255915 · Oak Crest Institute of Science
2018-09-20 – 2026-12-31 · HIV Prevention
What this study did
NCT04870671 · Eastern Virginia Medical School
2021-03-25 – 2023-01-31 · HIV/AIDS, Adherence, Medication, Drug Use
What this study did
NCT04302896 · Rhonda Brand
2020-08-31 – 2021-09-30 · Medication Adherence, HIV
What this study did
NCT03202511 · Indiana University
2017-06-23 – 2018-07-02 · Pre-Exposure Prophylaxis
What this study did
NCT03186482 · St. Stephens Clinical Research
2017-06-01 – 2018-01-10 · HIV
What this study did
NCT02762617 · Marla Keller
2017-02-24 – 2017-10-17 · Healthy, HIV
What this study did
NCT02431273 · Auritec Pharmaceuticals
2015-06 – 2016-12 · Human Immunodeficiency Virus (HIV) Prophylaxis
What this study did
NCT02722343 · CONRAD
2016-04 – 2016-08 · HIV
What this study did
NCT02006264 · Albert Einstein College of Medicine
2013-11-19 – 2014-11-06 · HIV
What this study did
NCT02039323 · University of North Carolina, Chapel Hill
2014-02 – 2014-04 · Healthy Adult Females
What this study did
NCT01136759 · National Institute of Allergy and Infectious Diseases (NIAID)
2011-03 – 2013-09 · HIV Infections
What this study did
NCT00120471 · National Institute of Allergy and Infectious Diseases (NIAID)
2006-11 – 2011-12 · HIV Infections
What this study did
NCT01108926 · St Stephens Aids Trust
2010-06 – 2010-10 · HIV Infection, HIV Infections
What this study did
NCT00903084 · Public Health Foundation Enterprises, Inc.
2009-06 – 2010-06 · HIV
What this study did
NCT00336778 · University of Maryland, Baltimore
2004-01 – 2008-04 · HIV Infections
What this study did
NCT00024986 · National Cancer Institute (NCI)
2001-10 – 2005-09 · HIV Infection
What this study did
NCT00002396 · Gilead Sciences
— · HIV Infections
What this study did
Other / comorbidity
NCT06356662 · The Fourth Affiliated Hospital of Zhejiang University School of Medicine
2024-01-23 – 2025-12-31 · Parkinson Disease
What this study did
NCT06816043 · Merck Sharp & Dohme LLC
2025-02-21 – 2025-06-17 · Healthy
What this study did
NCT05137548 · Antios Therapeutics, Inc
2021-10-27 – 2021-12-23 · Drug Interaction
What this study did
NCT07558967 · Haisco Pharmaceutical Group Co., Ltd.
2017-06-20 – 2017-11-20 · Healthy
What this study did
NCT03537404 · R-Pharm
2017-04-24 – 2017-06-30 · Healthy
What this study did
NCT03070405 · Inje University
2016-10 – 2017-05 · Healthy Volunteers
What this study did
NCT02557594 · Dong-A ST Co., Ltd.
2015-10-06 – 2016-03-08 · Healthy
What this study did
NCT01592305 · Hoffmann-La Roche
2012-05 – 2012-06 · Healthy Volunteer
What this study did
NCT01205139 · Tibotec Pharmaceuticals, Ireland
2010-11 – 2011-03 · Hepatitis C Virus
What this study did
NCT01080820 · Jazz Pharmaceuticals
2010-06 – 2010-12 · Healthy
What this study did
Phase 4 (79)
Chronic Hepatitis B
NCT05403047 · ANRS, Emerging Infectious Diseases
2023-08-22 – 2028-02 · Hepatitis B Virus - Chronic Active
What this study did
NCT05705427 · University of North Carolina, Chapel Hill
2023-08-17 – 2025-11-25 · Hepatitis B, Vertical Transmission of Infectious Disease
What this study did
NCT03476083 · New Discovery LLC
2018-06-10 – 2024-05 · Hepatitis B Infection, Congenital Malformation, Birth Defect, Viremia, Chronic Infection
What this study did
NCT03357822 · Tongji Hospital
2018-01-25 – 2022-07-25 · Chronic Hepatitis B
What this study did
NCT03013556 · Ruijin Hospital
2016-11 – 2021-12-31 · Chronic Hepatitis
What this study did
NCT02224456 · GlaxoSmithKline
2015-03-25 – 2020-12-04 · Hepatitis B, Chronic
What this study did
NCT03567382 · University of North Carolina, Chapel Hill
2018-09-24 – 2020-08-15 · Hepatitis B, Vertical Transmission of Infectious Disease
What this study did
NCT02937779 · ANRS, Emerging Infectious Diseases
2017-10-04 – 2020-03-31 · Hepatitis B Chronic Infection, Pregnancy
What this study did
NCT02463019 · E-DA Hospital
2015-01 – 2020-01 · Chronic Hepatitis B, Antiviral Treatment
What this study did
NCT01491295 · Taipei Veterans General Hospital, Taiwan
2012-09 – 2019-12 · Chronic Hepatitis B
What this study did
NCT03258710 · GlaxoSmithKline
2017-10-02 – 2019-11-25 · Hepatitis B, Chronic
What this study did
NCT02081469 · Chang Gung Memorial Hospital
2014-03-17 – 2019-08-05 · Hepatitis B, Chronic, Tumor
What this study did
NCT02308319 · Samsung Medical Center
2015-01 – 2019-06 · Carcinoma, Hepatocellular
What this study did
NCT02973646 · Third Affiliated Hospital, Sun Yat-Sen University
2016-01 – 2018-12 · Chronic Hepatitis b
What this study did
NCT01522625 · E-DA Hospital
2012-01 – 2018-12 · Chronic Hepatitis B
What this study did
NCT01488526 · New Discovery LLC
2012-03-01 – 2018-06-28 · Hepatitis B Infection, Chronic Infection, Viremia
What this study did
NCT02479880 · Gilead Sciences
2015-07-03 – 2018-04-11 · Hepatitis B
What this study did
NCT01639092 · Asan Medical Center
2012-09-28 – 2018-03-29 · Chronic Viral Hepatitis B Without Delta-agent
What this study did
NCT03468907 · Third Affiliated Hospital, Sun Yat-Sen University
2015-06-01 – 2017-12-31 · Hepatitis B, Chronic
What this study did
NCT02560649 · Ruijin Hospital
2015-05 – 2017-02 · Chronic Hepatitis B
What this study did
NCT01711567 · Korea University
2013-04 – 2016-11 · Chronic Hepatitis B
What this study did
NCT02238860 · Asian Institute Of Medical Sciences
2014-09 – 2016-09 · Cirrhosis Due to Hepatitis B
What this study did
NCT01320943 · Gilead Sciences
2011-04-26 – 2016-08-23 · Chronic Hepatitis B
What this study did
NCT02039362 · Hopital Lariboisière
2012-07 – 2016-07 · Pregnancy, HBV
What this study did
NCT01732367 · Keimyung University Dongsan Medical Center
2012-11 – 2016-04 · Chronic Hepatitis B
What this study did
NCT01588912 · Pusan National University Yangsan Hospital
2012-04 – 2014-12 · Chronic Hepatitis B
What this study did
NCT01597934 · Yonsei University
2012-08 – 2014-05 · Chronic Hepatitis B
What this study did
NCT01594905 · Yonsei University
2012-08 – 2014-04 · Chronic Hepatitis B
What this study did
NCT00651209 · Novartis Pharmaceuticals
2008-02 – 2011-12 · Hepatitis B, Chronic
What this study did
NCT00736190 · Gilead Sciences
2008-08 – 2010-07 · Chronic Hepatitis B
What this study did
NCT00662545 · University of California, San Francisco
2008-04 – 2010-05 · HIV Infections, Hepatitis B
What this study did
NCT01074645 · Govind Ballabh Pant Hospital
2007-11 – 2009-10 · Acute on Chronic Liver Failure, Hepatitis B
What this study did
HIV
NCT07631897 · Shanghai Public Health Clinical Center
2026-06 – 2028-12 · HIV, Art Therapy, TB - Tuberculosis
What this study did
NCT07673965 · University of Witwatersrand, South Africa
2026-10-05 – 2027-11-30 · HIV (Human Immunodeficiency Virus), Sleep
What this study did
NCT06485154 · University of Witwatersrand, South Africa
2024-06-01 – 2026-08-31 · HIV Prevention
What this study did
NCT07006246 · Professor Francois Venter
2023-05-19 – 2025-11-30 · HIV Infection
What this study did
NCT06602622 · Instituto Mexicano del Seguro Social
2024-08-14 – 2025-11-14 · HIV, HIV Associate Weight Loss, HIV-1 Infection, Integrase Inhibitors, HIV; HIV PROTEASE INHIB, Weight Change, Weight Loss
What this study did
NCT05326971 · Jussi Sutinen
2023-01-19 – 2025-06-01 · HIV Infections, Weight Gain
What this study did
NCT04636437 · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
2021-07-27 – 2024-10-18 · HIV Infections
What this study did
NCT04665375 · University Health Network, Toronto
2021-04-26 – 2024-03-31 · Hiv, Weight Gain
What this study did
NCT03675815 · Kirby Institute
2019-12-05 – 2024-01-15 · HIV Infections
What this study did
NCT04903847 · Thomas Benfield
2021-02-02 – 2023-02-02 · Hiv, HIV Infections, HIV Lipodystrophy, Osteoporosis, Renal Insufficiency, Weight Gain, Obesity
What this study did
NCT04298697 · Emory University
2020-02-28 – 2022-08-09 · Human Immunodeficiency Virus
What this study did
NCT03126370 · University of Colorado, Denver
2018-01-08 – 2019-10-01 · Hepatitis C, HIV Coinfection
What this study did
NCT02935075 · Shanghai Public Health Clinical Center
2018-03-05 – 2019-08-31 · HIV Infections
What this study did
NCT01641367 · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
2013-02-22 – 2018-12-31 · HIV-1 Infection
What this study did
NCT02593409 · MRC/UVRI and LSHTM Uganda Research Unit
2017-05-25 – 2018-06 · HIV-1 Infections
What this study did
Early phase / not applicable (36)
Chronic Hepatitis B
NCT04195074 · Third Affiliated Hospital, Sun Yat-Sen University
2019-01-01 – 2024-12-31 · Chronic Hepatitis b
What this study did
NCT03957629 · Third Affiliated Hospital, Sun Yat-Sen University
2019-11-06 – 2023-07-30 · Hepatitis B, Liver Fibrosis
What this study did
NCT04998838 · Myanmar Liver Foundation
2018-07-01 – 2023-06-30 · Hepatitis B
What this study did
NCT03920605 · Third Affiliated Hospital, Sun Yat-Sen University
2019-02-01 – 2021-12-31 · Hepatitis B, Liver Fibrosis
What this study did
NCT03214302 · Beijing Ditan Hospital
2017-01-01 – 2019-12-30 · Chronic Hepatitis B
What this study did
NCT02287857 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2014-09 – 2019-10 · Chronic Hepatitis B
What this study did
NCT00973219 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2009-09 – 2019-10 · Chronic Hepatitis B
What this study did
NCT02510963 · First Affiliated Hospital Xi'an Jiaotong University
2015-11 – 2017-08 · Hepatitis B, Chronic
What this study did
NCT01918631 · Chinese University of Hong Kong
2013-08 – 2017-01-31 · Chronic Heptitis B
What this study did
NCT01728935 · The University of Hong Kong
2008-04 – 2013-03 · Chronic Hepatitis B
What this study did
HIV
NCT05477407 · Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
2022-10-06 – 2025-01-01 · HIV Infections
What this study did
NCT04583267 · Yonsei University
2018-08-28 – 2022-12 · HIV Infections
What this study did
NCT00087464 · National Institute of Allergy and Infectious Diseases (NIAID)
— · HIV Infections
What this study did
NCT03251690 · Mahidol University
2016-10-27 – 2018-04-30 · Anti-Retroviral Agents, Efavirenz, HIV-1-infection, Sustained Virologic Response, Dyslipidemias, Rilpivirine
What this study did
NCT02449733 · Emory University
2015-05 – 2017-03 · HIV
What this study did
NCT02043015 · Emory University
2015-02 – 2017-03 · HIV
What this study did
NCT01844297 · Peking Union Medical College
2013-05 – 2015-12 · AIDS/HIV PROBLEM
What this study did
NCT01632995 · National Institute of Allergy and Infectious Diseases (NIAID)
2012-10 – 2015-02 · HIV Infections
What this study did
NCT00525733 · Rockefeller University
2007-10 – 2013-12 · HIV Infections
What this study did
NCT00608569 · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
2009-03 – 2012-09 · HIV Infections
What this study did
NCT02404259 · The HIV Netherlands Australia Thailand Research Collaboration
2010-06 – 2012-05 · HIV
What this study did
NCT00641641 · Kirby Institute
2008-03 – 2011-06 · HIV Infection
What this study did
NCT00863668 · University of Minnesota
2009-03 – 2011-03 · HIV Infection, HIV Infections
What this study did
NCT00414518 · University of Colorado, Denver
2007-01 – 2010-02 · HIV Infections
What this study did
NCT00051831 · National Institute of Allergy and Infectious Diseases (NIAID)
2003-10 – 2008-05 · HIV Infections
What this study did
NCT00109603 · National Institute of Allergy and Infectious Diseases (NIAID)
2005-05 – 2007-11 · HIV Infections, Dyslipidemia, Hyperlipidemia, Hypercholesterolemia, Hypertriglyceridemia
What this study did
NCT00100581 · National Institute of Allergy and Infectious Diseases (NIAID)
est. completion 2007-01 · HIV Infections, Hepatitis C
What this study did
NCT00344981 · University of Maryland, Baltimore
2003-06 – 2006-11 · HIV Infections, AIDS
What this study did
NCT00034086 · National Institute of Allergy and Infectious Diseases (NIAID)
est. completion 2006-06 · HIV Infections
What this study did
NCT00028366 · National Institute of Allergy and Infectious Diseases (NIAID)
est. completion 2005-07 · HIV Infections
What this study did
NCT00011089 · Gilead Sciences
started 2001-02 · HIV Infections
What this study did
NCT00016588 · Gilead Sciences
started 2001-05 · HIV Infections
What this study did
NCT00002453 · Gilead Sciences
started 1999-12 · HIV Infections
What this study did
Other / comorbidity
NCT04593680 · Thai Red Cross AIDS Research Centre
2022-01-24 – 2025-10-01 · Drug Interaction
What this study did
NCT02454764 · Institute of Liver and Biliary Sciences, India
est. completion 2018-01-01 · HBV
What this study did
Used as active comparator (65)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (31)
Chronic Hepatitis B
NCT04846491 · Xiamen Amoytop Biotech Co., Ltd.
2019-12-04 – 2023-12-07 · Chronic Hepatitis B
What this study did
NCT02836236 · Gilead Sciences
2015-06-19 – 2023-09-18 · HBV, Chronic HBV Infection
What this study did
NCT02836249 · Gilead Sciences
2015-06-19 – 2023-08-31 · HBV, Chronic HBV Infection
What this study did
NCT01940471 · Gilead Sciences
2013-09-11 – 2022-10-13 · HBeAg-positive Chronic Hepatitis B
What this study did
NCT01940341 · Gilead Sciences
2013-09-12 – 2022-08-31 · HBeAg-negative Chronic Hepatitis B
What this study did
NCT02979613 · Gilead Sciences
2016-12-29 – 2020-01-30 · Chronic Hepatitis B
What this study did
NCT02967939 · Dong-A ST Co., Ltd.
2017-03-28 – 2019-07-15 · Hepatitis B, Chronic
What this study did
NCT02805738 · Chong Kun Dang Pharmaceutical
2016-04 – 2018-03 · Chronic Hepatitis B
What this study did
HIV
NCT06497465 · Johns Hopkins University
2025-09-18 – 2029-01-31 · Tuberculosis, HIV
What this study did
NCT07044297 · Merck Sharp & Dohme LLC
2025-07-31 – 2027-07-22 · Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
What this study did
NCT03164564 · National Institute of Allergy and Infectious Diseases (NIAID)
2017-11-07 – 2026-10-17 · HIV Infections
What this study did
NCT04644029 · Merck Sharp & Dohme LLC
2021-02-24 – 2024-06-11 · HIV-I, Human Immunodeficiency Virus Type 1, Prophylaxis
What this study did
NCT04937881 · University of California, Los Angeles
2022-06-13 – 2023-09-01 · Hiv
What this study did
NCT04652700 · Merck Sharp & Dohme LLC
2021-03-15 – 2023-08-04 · HIV Preexposure Prophylaxis
What this study did
NCT02831673 · ViiV Healthcare
2016-07-21 – 2022-08-15 · Infection, Human Immunodeficiency Virus, HIV Infections
What this study did
NCT02831764 · ViiV Healthcare
2016-07-18 – 2022-06-29 · Infection, Human Immunodeficiency Virus, HIV Infections
What this study did
NCT02121795 · Gilead Sciences
2014-05-06 – 2019-03-01 · HIV-1 Infection
What this study did
NCT01797445 · Gilead Sciences
2013-03-12 – 2018-10-03 · HIV, HIV Infections
What this study did
NCT02369965 · Frontier Biotechnologies Inc.
2014-02-19 – 2018-04-02 · HIV Infections, AIDS
What this study did
NCT01780506 · Gilead Sciences
2012-12-26 – 2017-09-06 · HIV, HIV Infections
What this study did
NCT00427297 · University of Washington
2007-09 – 2009-12 · HIV Infections
What this study did
Phase 2 (12)
Chronic Hepatitis B
HIV
NCT04066881 · MRC/UVRI and LSHTM Uganda Research Unit
2020-12-15 – 2024-12-31 · HIV Infections
What this study did
NCT03272347 · Merck Sharp & Dohme LLC
2017-11-27 – 2022-03-09 · HIV-1 Infection
What this study did
NCT01497899 · Gilead Sciences
2011-12-28 – 2016-08-22 · Acquired Immunodeficiency Syndrome, HIV Infections
What this study did
NCT00752856 · University of California, San Diego
2008-08-26 – 2014-02-11 · HIV Infections
What this study did
NCT01565850 · Gilead Sciences
2012-04 – 2014-02 · Acquired Immunodeficiency Syndrome, HIV Infections
What this study did
NCT01737359 · RFS Pharma, LLC
2012-12 – 2013-03 · Human Immunodeficiency Virus Infection
What this study did
NCT00551018 · Merck Sharp & Dohme LLC
2007-12 – 2010-10 · HIV Infections
What this study did
NCT00119379 · National Institute of Allergy and Infectious Diseases (NIAID)
2005-04 – 2008-10 · HIV Infections, Lipodystrophy, Metabolic Diseases, Nutrition Disorders
What this study did
Phase 1/2 (1)
HIV
NCT00036634 · Gilead Sciences
2002-03 – 2003-02 · HIV Infections
What this study did
Phase 1 (3)
Chronic Hepatitis B
NCT03770624 · Qilu Pharmaceutical Co., Ltd.
2018-10-16 – 2019-04-30 · Chronic Hepatitis b
What this study did
NCT02589457 · Chong Kun Dang Pharmaceutical
2015-10 – 2015-12 · Chronic Hepatitis B
What this study did
Other / comorbidity
NCT02902523 · Huons Co., Ltd.
2016-09 – 2016-11 · Healthy
What this study did
Phase 4 (11)
Chronic Hepatitis B
NCT07668934 · The Third Affiliated Hospital of Guangzhou Medical University
2025-03-31 – 2028-03-30 · Hepatitis B Infection, Pregnant Women, Early Pregnancy
What this study did
NCT03356834 · Humanity and Health Research Centre
2017-12-01 – 2024-10-31 · Chronic Hepatitis B
What this study did
NCT04202536 · IlDong Pharmaceutical Co Ltd
2019-05-29 – 2021-10 · Hepatitis B, Besifovir Dipivoxil Maleate, Tenofovir Disoproxil Fumarate
What this study did
NCT03241641 · Young-Suk Lim
2017-10-26 – 2021-03-25 · Chronic Hepatitis b
What this study did
NCT05286346 · Samjin Pharmaceutical Co., Ltd.
2018-10-12 – 2020-08-10 · Chronic Hepatitis b
What this study did
NCT03485534 · Daewoong Pharmaceutical Co. LTD.
2018-01-23 – 2019-11-04 · Hepatitis B, Chronic
What this study did
NCT05282407 · Samjin Pharmaceutical Co., Ltd.
2017-11-20 – 2019-04-17 · Chronic Hepatitis B
What this study did
NCT01379508 · Novartis Pharmaceuticals
2011-03-21 – 2015-12-10 · Chronic Hepatitis B
What this study did
NCT01277601 · Gilead Sciences
2011-04 – 2015-07 · Chronic Hepatitis B
What this study did
HIV
NCT01829802 · Pedro Cahn
2014-05 – 2017-10 · Chronic Infection With HIV
What this study did
NCT00627055 · The HIV Netherlands Australia Thailand Research Collaboration
2008-05 – 2010-11 · HIV Infections
What this study did
Early phase / not applicable (7)
Chronic Hepatitis B
NCT06947356 · Guangzhou 8th People's Hospital
2025-05-03 – 2028-05-01 · Hepatitis B
What this study did
NCT03920618 · Third Affiliated Hospital, Sun Yat-Sen University
2019-02-21 – 2024-12-31 · Hepatitis B, Acute-On-Chronic Liver Failure
What this study did
NCT04501224 · Third Affiliated Hospital, Sun Yat-Sen University
2020-08-03 – 2024-04-30 · Chronic Hepatitis b, Cirrhosis Due to Hepatitis B
What this study did
NCT04196998 · Third Affiliated Hospital, Sun Yat-Sen University
2019-01-01 – 2023-12 · Hepatitis B, Compensated Cirrhosis
What this study did
NCT03919565 · Third Affiliated Hospital, Sun Yat-Sen University
2019-02-01 – 2021-12-31 · Hepatitis B, Liver Fibrosis
What this study did
HIV
NCT07497594 · Oswaldo Cruz Foundation
2026-02-03 – 2029-09 · Contact With or Exposure to Human Immunodeficiency Virus
What this study did
NCT03405194 · Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic
2018-05-01 – 2020-07-01 · HIV/AIDS
What this study did
Studied as part of a combination product (57)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Phase 3 (14)
HIV
NCT07071623 · Merck Sharp & Dohme LLC
2025-11-10 – 2027-10-18 · Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
What this study did
NCT06138600 · University of Witwatersrand, South Africa
2023-11-01 – 2026-01-31 · HIV Infections
What this study did
NCT03048422 · National Institute of Allergy and Infectious Diseases (NIAID)
2018-01-19 – 2020-10-03 · HIV Infections
What this study did
NCT01435018 · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
2013-10-01 – 2019-08-29 · HIV-1 Infection
What this study did
NCT01061151 · National Institute of Allergy and Infectious Diseases (NIAID)
2011-03-01 – 2016-09-30 · HIV Infections
What this study did
NCT01352715 · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
2012-03-13 – 2014-10-29 · HIV-1 Infection
What this study did
NCT00811954 · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
2009-05 – 2013-06 · HIV Infection
What this study did
NCT00089505 · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
2006-11 – 2011-02 · HIV Infections
What this study did
NCT00118898 · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
2005-09 – 2009-11 · HIV Infections
What this study did
NCT00105079 · Hoffmann-La Roche
2005-04 – 2008-07 · HIV Infections
What this study did
Other / comorbidity
NCT04890626 · Instituto de Investigación Hospital Universitario La Paz
2020-04-04 – 2023-07-17 · SARS-CoV-2 Infection
What this study did
Phase 2/3 (2)
Chronic Hepatitis B
NCT00391638 · French National Agency for Research on AIDS and Viral Hepatitis
2007-01 – 2012-10 · Hepatitis B, HIV Infections
What this study did
HIV
NCT00448669 · Centers for Disease Control and Prevention
2007-03 – 2011-03 · HIV Infections
What this study did
Phase 2 (11)
HIV
NCT06513312 · Gilead Sciences
2024-10-07 – 2028-11 · Pre-Exposure Prophylaxis of HIV Infection
What this study did
NCT06101342 · Gilead Sciences
2023-12-13 – 2028-01 · Pre-Exposure Prophylaxis of HIV Infection
What this study did
NCT06101329 · Gilead Sciences
2023-11-17 – 2028-01 · Pre-Exposure Prophylaxis of HIV Infection
What this study did
NCT03386578 · National Institute of Allergy and Infectious Diseases (NIAID)
2018-07-03 – 2024-02-24 · HIV Infections
What this study did
NCT01769456 · University of North Carolina, Chapel Hill
2013-03 – 2016-11 · HIV Infection
What this study did
NCT01605890 · ANRS, Emerging Infectious Diseases
2012-07 – 2015-12 · HIV-2 Infection
What this study did
NCT01772823 · University of North Carolina, Chapel Hill
2012-11 – 2015-11 · HIV Infection
What this study did
NCT00099632 · National Institute of Allergy and Infectious Diseases (NIAID)
2006-03 – 2011-11 · HIV Infections
What this study did
NCT00090779 · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
2005-01 – 2011-05 · HIV Infections
What this study did
Phase 1/2 (1)
HIV
NCT01632891 · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
2014-01-10 – 2016-06-19 · HIV-1 Infection, Pf Subclinical Parasitemia
What this study did
Phase 1 (9)
HIV
NCT03270969 · University of Nebraska
2018-01-05 – 2018-09-10 · HIV Prevention
What this study did
NCT03060785 · Johns Hopkins University
2016-03-08 – 2018-05-31 · HIV Prevention
What this study did
NCT01040091 · National Institute of Allergy and Infectious Diseases (NIAID)
2009-12 – 2014-04 · HIV Infections
What this study did
NCT00545558 · University of Cincinnati
2006-04 – 2012-03 · Hepatitis C, HIV Infections
What this study did
NCT00076791 · National Institute of Allergy and Infectious Diseases (NIAID)
2004-03 – 2011-03 · HIV Infections
What this study did
NCT00660972 · National Institute of Allergy and Infectious Diseases (NIAID)
2008-05 – 2010-04 · HIV Infections
What this study did
Other / comorbidity
NCT07795307 · Brigham and Women's Hospital
2026-12 – 2028-09 · Alzheimer's Disease
What this study did
NCT02583464 · Laboratorio Elea Phoenix S.A.
2014-09 – 2014-12 · Acquired Immunodeficiency Syndrome
What this study did
Phase 4 (15)
HIV
NCT07901101 · University of South Florida
2026-11 – 2028-05 · HIV Prevention, Pre-Exposure Prophylaxis (PrEP)
What this study did
NCT04050371 · University of California, San Francisco
2017-08-03 – 2018-05-23 · HIV Prevention, Transgender Health
What this study did
NCT02206555 · Kirby Institute
2014-11-14 – 2017-12-20 · HIV
What this study did
NCT02180438 · University of Washington
2014-09 – 2017-01 · HIV-2 Infection
What this study did
NCT02065986 · MRC [ycm]
2012-10 – 2016-10 · HIV
What this study did
NCT01285050 · Johns Hopkins University
2011-01 – 2015-04 · HIV Infection, Hepatitis C
What this study did
NCT01234116 · Henry Ford Health System
2011-02 – 2013-05 · Human Immunodeficiency Virus
What this study did
NCT00724711 · Gilead Sciences
2008-07 – 2011-04 · HIV Infection
What this study did
NCT00442962 · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
2007-05 – 2010-12 · HIV Infections
What this study did
NCT00084136 · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
2005-05 – 2010-05 · HIV Infections
What this study did
NCT00552240 · Boehringer Ingelheim
2007-09 – 2010-03 · HIV Infections
What this study did
NCT00055120 · National Institute of Allergy and Infectious Diseases (NIAID)
2003-03 – 2007-08 · HIV Infections, AIDS-Related Opportunistic Infections
What this study did
Other / comorbidity
NCT03309566 · Laboratorio Elea Phoenix S.A.
2016-09-04 – 2017-02-28 · Healthy
What this study did
Early phase / not applicable (5)
HIV
NCT07584122 · Oswaldo Cruz Foundation
2025-09-01 – 2026-12 · HIV Infections
What this study did
NCT01450189 · University of North Carolina, Chapel Hill
2011-10 – 2014-07 · HIV
What this study did
NCT04318210 · Centers for Disease Control and Prevention
2012-10 – 2014-07 · HIV Infections
What this study did
NCT00357552 · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
2008-01 – 2012-05 · HIV Infections
What this study did
Other / comorbidity
NCT02968576 · University of Colorado, Denver
2016-12 – 2017-06 · Healthy Volunteers, Pharmacokinetics
What this study did
Appears in other studies (18)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (11)
Chronic Hepatitis B
NCT04157699 · Qilu Pharmaceutical Co., Ltd.
2019-07-26 – 2022-10 · Chronic Hepatitis b
What this study did
NCT05238844 · Antios Therapeutics, Inc
2022-04-11 – 2022-05-25 · Chronic Hepatitis b
What this study did
NCT03361956 · Janssen Sciences Ireland UC
2018-02-13 – 2020-08-13 · Hepatitis B
What this study did
NCT02452528 · Arrowhead Pharmaceuticals
2015-08 – 2016-12 · Chronic Hepatitis B
What this study did
HIV
NCT07871552 · The University of Texas Health Science Center, Houston
2026-10-30 – 2028-10-15 · Epigenetic Aging
What this study did
NCT06338826 · ANRS, Emerging Infectious Diseases
2025-02-01 – 2027-09-30 · HIV Infections, HBV Coinfection
What this study did
NCT04109183 · Henan Genuine Biotech Co., Ltd.
2017-10-10 – 2019-03-06 · AIDS
What this study did
Phase 4 (5)
Chronic Hepatitis B
NCT02774837 · Seng Gee Lim
2016-04 – 2020-07 · Chronic Hepatitis B
What this study did
NCT03253250 · Huashan Hospital
2017-09-01 – 2019-12 · Chronic Hepatitis b, Hepatic Carcinoma
What this study did
NCT01639066 · Asan Medical Center
2012-09-25 – 2017-09-22 · Chronic Viral Hepatitis B Without Delta-agent
What this study did
HIV
NCT05898841 · Fundacion SEIMC-GESIDA
2023-05-26 – 2025-07-07 · HIV Infections, Fatty Liver Disease
What this study did
NCT00389194 · International Antiviral Therapy Evaluation Center
2006-04 – 2008-10 · HIV Infections
What this study did
Early phase / not applicable (2)
HIV
NCT03394196 · University of Washington
2018-07-04 – 2020-05-31 · HIV-2 Infection
What this study did
NCT01583439 · Harvard School of Public Health (HSPH)
2012-09 – 2013-09 · HIV Infections
What this study did

Competitive landscape

This drug's own stage for Chronic Hepatitis B: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Tenofovir Disoproxil Fumarate (Viread): this drugApprovedSmall moleculeHIV reverse transcriptase (RT)Reliable signal
NCT00116805: Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48 (Baseline; Week 48): TDF-TDF 66.5 percentage of participants | ADV 10 mg 12.2 percentage of participants
NCT00117676: Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48 (Baseline; Week 48): TDF-TDF — Yes: 70.8 percentage of participants; No: 29.2 percentage of participants | ADV-TDF — Yes: 48.8 percentage of participants; No: 51.2 percentage of participants
Entecavir (Baraclude)ApprovedSmall moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
Hepatitis B Immune Globulin (HepaGam B)ApprovedProtein / enzyme therapeuticHBsAgnot yet gradedNo reviewed efficacy summary in this indication
Interferon Alfa-2b (Intron A)ApprovedBiologic (subtype unspecified)Type I interferon receptornot yet gradedNo reviewed efficacy summary in this indication
Lamivudine (Epivir-HBV)
ApprovedUS marketing discontinued
Small moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
Peginterferon Alfa-2a (Pegasys)Approved—Type I interferon receptorPartial signalFeatured results are non-efficacy only in this race
Tenofovir Alafenamide (Vemlidy)ApprovedSmall moleculeHBV polymerase (reverse transcriptase)Reliable signalFeatured results are non-efficacy only in this race
Besifovir Dipivoxil (Besivo)Phase 3Small moleculeHBV polymerase (reverse transcriptase)Partial signal
NCT01937806: Primary endpoint at week 48: 80.9% with besifovir vs 84.9% with tenofovir disoproxil fumarate met the virologic response endpoint, showing non-inferiority (Ahn et al., Clin Gastroenterol Hepatol 2019).
Hepatitis B Immune Globulin (I.V.-Hepabig)Phase 3Polyclonal Antibody (human Hepatitis B Immunoglobulin)HBsAgnot yet gradedNo reviewed efficacy summary in this indication
Tenofovir Amibufenamide (Hengmu)Phase 3Small moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
TQA3605Phase 3—HBV core proteinnot yet gradedNo reviewed efficacy summary in this indication
TVAX-008Phase 3VaccineHepatitis B virus antigens (HBsAg + HBcAg)not yet gradedNo reviewed efficacy summary in this indication
AHB-171Phase 2RNA / oligonucleotideHBV RNAnot yet gradedNo reviewed efficacy summary in this indication
Daplusiran / TomligisiranPhase 2RNA / oligonucleotideHBV RNA (X and S transcripts)not yet gradedNo reviewed efficacy summary in this indication
EnvafolimabPhase 2Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
HepalatidePhase 2PeptideNTCPnot yet gradedNo reviewed efficacy summary in this indication
Libevitug (HH-003)Phase 2Monoclonal antibodyHBV/HDV large envelope protein (PreS1 domain)not yet gradedNo reviewed efficacy summary in this indication
MetacavirPhase 2Small moleculeHBV reverse transcriptase (nucleoside analog)not yet gradedNo reviewed efficacy summary in this indication
REP 2139-MgPhase 2—HBsAg release (nucleic acid polymer)not yet gradedNo reviewed efficacy summary in this indication
T101Phase 2Biologic (subtype unspecified)HBV core, polymerase and envelope antigensnot yet gradedNo reviewed efficacy summary in this indication
TQA3810Phase 2—TLR8not yet gradedNo reviewed efficacy summary in this indication
CRMA-1001Phase 1/2Gene therapy / editingHBV genome (cccDNA and integrated DNA)not yet gradedNo reviewed efficacy summary in this indication
HepadvaxPhase 1/2VaccineHBsAg (PreS) immunizationnot yet gradedNo reviewed efficacy summary in this indication
Human Serum Albumin / Interferon Alpha2b Fusion ProteinPhase 1/2Biologic (subtype unspecified)Type I interferon receptornot yet gradedNo reviewed efficacy summary in this indication
LW231Phase 1/2——not yet gradedNo reviewed efficacy summary in this indication
PA1010Phase 1/2——not yet gradedNo reviewed efficacy summary in this indication
TQA3038Phase 1/2——not yet gradedNo reviewed efficacy summary in this indication
ACT201Phase 1RNA / oligonucleotideHBsAgnot yet gradedNo reviewed efficacy summary in this indication
CB06-036Phase 1—TLR8not yet gradedNo reviewed efficacy summary in this indication
DA-2803Phase 1——not yet gradedNo reviewed efficacy summary in this indication
Entecavir (Cavir)
Phase 1(overall)
Small moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
HECN30227Phase 1——not yet gradedNo reviewed efficacy summary in this indication
SA1211Phase 1RNA / oligonucleotideHepatitis B virus RNA (dual-target siRNA)not yet gradedNo reviewed efficacy summary in this indication
TVAX-028Phase 1——not yet gradedNo reviewed efficacy summary in this indication
Adefovir Dipivoxil (Hepsera)DiscontinuedSmall moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
Obeticholic Acid (Ocaliva)Discontinued—FXRnot yet gradedNo reviewed efficacy summary in this indication
PamrevlumabDiscontinuedMonoclonal antibodyCTGFnot yet gradedNo reviewed efficacy summary in this indication
Telbivudine (Tyzeka)Discontinued—HBV polymerase (reverse transcriptase)Partial signal
NCT00076336: Protocol composite at week 52 (HBV DNA <10,000 copies/mL, normal ALT, Child-Turcotte-Pugh score improved or stable), telbivudine vs lamivudine, ITT missing=failure: 56.2% vs 54.0%, non-inferiority not achieved (Chan et al., Aliment Pharmacol Ther 2012). missed

Upcoming events

(11 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Tenofovir disoproxil fumarate (Viread) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
November 2026 (1)
Phase 2Long CovidRecruiting
Est. primary completion 2026-11 · NCT06511063 · CT.gov ↗
What to watch
2027 (3)
August 2027 (2)
Phase 4Chronic Hepatitis BActive not recruiting
Est. primary completion 2027-08 · NCT05403047 · CT.gov ↗
What to watch
Phase 4HIVNot yet recruiting
Est. primary completion 2027-08-31 · NCT07673965 · CT.gov ↗
What to watch
December 2027 (1)
Phase 3HIVRecruiting
Est. primary completion 2027-12-05 · NCT07075146 · CT.gov ↗
What to watch
2028 (6)
January 2028 (2)
Phase 3HIVRecruiting
Est. primary completion 2028-01 · NCT06203132 · CT.gov ↗
What to watch
Phase 2Healthy Volunteer, Weight Gain, Metabolic Effects, Integrase Strand Transfer InhibitorsRecruiting
Est. primary completion 2028-01-31 · NCT05652478 · CT.gov ↗
What to watch
May 2028 (1)
Phase 2HTLV-1 Infection, HTLV I Associated Myelopathies, HTLV I Associated T Cell Leukemia Lymphoma, NeuritisRecruiting
Est. primary completion 2028-05 · NCT07555431 · CT.gov ↗
What to watch
June 2028 (1)
Phase 4HIVNot yet recruiting
Est. primary completion 2028-06 · NCT07631897 · CT.gov ↗
What to watch
September 2028 (1)
Phase 3Chronic Hepatitis BNot yet recruiting
Est. primary completion 2028-09 · NCT07797231 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2HIVRecruiting
Est. primary completion 2028-11-12 · NCT04375800 · CT.gov ↗
What to watch
2034 (1)
December 2034 (1)
Phase 1Chronic Hepatitis BNot yet recruiting
Est. primary completion 2034-12-31 · NCT07553767 · CT.gov ↗
What to watch

See the full readout calendar ↗